Caring Brands (NASDAQ:CABR) Releases Quarterly Earnings Results

Posted by Brian Himes on May 12th, 2026

Caring Brands (NASDAQ:CABR – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.27) earnings per share for the quarter, Zacks reports.

Caring Brands Stock Up 17.6%

CABR stock traded up $0.16 during midday trading on Tuesday, reaching $1.07. 173,039 shares of the company’s stock traded hands, compared to its average volume of 123,815. The firm has a market capitalization of $9.57 million and a P/E ratio of -2.89. The firm has a fifty day simple moving average of $1.03. The company has a debt-to-equity ratio of 0.03, a quick ratio of 13.09 and a current ratio of 13.16. Caring Brands has a 52 week low of $0.71 and a 52 week high of $5.35.

Institutional Trading of Caring Brands

An institutional investor recently bought a new position in Caring Brands stock. Jane Street Group LLC bought a new stake in Caring Brands, Inc. (NASDAQ:CABR – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned approximately 0.25% of Caring Brands as of its most recent SEC filing.

Wall Street Analyst Weigh In

Separately, Weiss Ratings began coverage on shares of Caring Brands in a research note on Monday, January 26th. They issued a “sell (e)” rating for the company. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Caring Brands has an average rating of “Sell”.

Read Our Latest Research Report on Caring Brands

Caring Brands Company Profile

(Get Free Report)

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.